Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Regencell Bioscience Holdings Limited

RGCNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed May 29, 2026Accepted May 29, 2026, 6:20 AM EDTFiling CIK 1829667Accession 0001213900-26-062409
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-05-27
Issuer
Regencell Bioscience Holdings Ltd
Issuer CIK
0001829667
Trading symbol
RGC

Reporting owner 1

Name
LO WILLIAM WING YAN DR
Reporting owner CIK
0001134441
Relationship
Director
Address
C/O 9/F CHINACHEM LEIGHTON PLAZA, 29 LEIGHTON ROAD, CAUSEWAY BAY, HONG KONG, CHINA, F4

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock option (right to purchase)0.84[F1]2026-05-27D · Form 470,600D[F2][F2][F2]Ordinary shares, par value $0.0000170,600521,630D
Table key
D · Form 4
Disposition to the issuer under Rule 16b-3(e)
D
Direct

Footnotes

F1
The exercise price has given effect to the share split(s) of the Issuer since the date of grant of the option.↩ 1
F2
On May 27, 2026, the Issuer repurchased from the Reporting Person options to purchase 70,600 ordinary shares of the Issuer at a price of $15.00 per option. The aggregate consideration payable to the Reporting Person under the Option Repurchase Agreement is further reduced by the aggregate exercise price of the repurchased options.↩ 1↩ 2↩ 3

Signature 1

Signed
/s/ James Wai Hong Chung, attorney-in-fact
Date
2026-05-29

Company context

We are an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. Our goal is to save and improve the lives of the patients, their families and caregivers and become a market leader for natural and holistic treatments for neurological disorders globally.

Current securities

Recent company filings

  1. 4 filingNov 17, 2026
  2. 144 filingNov 17, 2026
  3. S-8 filingNov 16, 2026
  4. 20-F filingOct 7, 2026
  5. 6-K filingMay 22, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.